Key Highlights
- Charles River Laboratories shares surged more than 10% after non-GAAP earnings per share of 3.02 dollars beat the 2.74 dollar consensus estimate by over 10%.
- Revenue of 1.00 billion dollars beat the roughly 977 to 980 million dollar consensus, even as it declined 2.7% year over year, while organic revenue growth turned positive at 0.1%, the strongest pace since the third quarter of 2023.
- The company raised full-year 2026 non-GAAP earnings per share guidance to a range of 11.15 to 11.45 dollars, up from a prior range of 10.80 to 11.30 dollars.
- Discovery and Safety Assessment net bookings rose 12.6% sequentially to 701 million dollars, with a net book-to-bill ratio of 1.19 times, the highest level in nearly four years.
A Broad-Based Beat Signals Stabilizing Demand
Charles River Laboratories (NYSE:CRL) shares surged more than 10% following second-quarter results that beat estimates across nearly every major metric, with non-GAAP earnings per share of 3.02 dollars topping the 2.74 dollar consensus by more than 10% and revenue of 1.00 billion dollars beating the roughly 977 to 980 million dollar consensus estimate despite declining 2.7% year over year. Organic revenue growth turned positive at 0.1%, marking the company's strongest organic growth pace since the third quarter of 2023 and suggesting an inflection point after a prolonged period of demand softness.
Operating margin rose 420 basis points sequentially to 20.5%, driven by benefits from recent divestitures and easing discrete margin headwinds, while non-GAAP earnings per share increased 47% sequentially, exceeding the company's own prior guidance of at least 30% sequential growth. This combination of returning organic growth and expanding margins suggests the improvement extends beyond simple cost-cutting into genuine demand recovery.
Discovery and Safety Assessment Segment Shows Strongest Momentum in Years
The Discovery and Safety Assessment segment delivered particularly strong results, with net bookings rising 12.6% sequentially to 701 million dollars and backlog reaching 1.97 billion dollars, while the segment's net book-to-bill ratio of 1.19 times marked the highest level in nearly four years and the third consecutive quarter above 1.0. Segment organic revenue grew 0.2%, the first growth in that specific segment since the third quarter of 2023, prompting the company to raise its full-year outlook for the segment to low single-digit organic growth.
This sustained improvement in bookings and book-to-bill ratios provides a meaningful forward indicator of demand recovery, since bookings today typically translate into revenue over subsequent quarters, suggesting the positive organic growth trend could continue building through the remainder of the year if current booking momentum persists.
Portfolio Actions and Cost Reductions Drive Margin Expansion
The company completed divestitures of its European Discovery Services sites, CDMO business and Cell Solutions business in May 2026, contributing to a Manufacturing Solutions segment margin of 37.8% in the second quarter, with margins expected to approach 40% in the second half of the year. Management expects at least 500 basis points of margin improvement in the second half of 2026 compared with the first half, with roughly half attributable to completed portfolio actions, including divestitures and lower non-human primate sourcing costs following a Cambodia-based acquisition, and the remainder from lower corporate costs.
Full-year 2026 guidance now calls for organic revenue growth of flat to 1%, a 150 basis point improvement from prior guidance, alongside reported revenue expected to decline 2.5% to 3.5% due to the divestitures, and free cash flow guidance raised to a range of 400 million to 420 million dollars from a prior range of 375 million to 400 million dollars. Persistent softness remains in the Research Models and Services segment and North American academic and government demand, which the company attributed to flat National Institutes of Health budgets.
Conclusion
Charles River Laboratories' second-quarter results and raised guidance suggest early signs of stabilization in biotech and pharmaceutical research spending after a prolonged downturn, reinforced by similarly positive results this week from other diagnostics and life sciences companies. The strength in Discovery and Safety Assessment bookings and book-to-bill ratios provides a credible forward signal that the return to organic growth could prove durable rather than a single-quarter anomaly. Whether North American academic and government demand also begins recovering, particularly given continued flat NIH funding levels, is likely to determine how broad-based this recovery ultimately becomes.






Please wait processing your request...